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Glutamine and GABA alterations in cingulate cortex may
underlie alcohol drinking in a rat model of co-occurring
alcohol use disorder and schizophrenia: an 1H-MRS study
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Patrick McCunn1,6, Xi Chen2,3,4,6, Barjor Gimi2, Alan I. Green5 and Jibran Y. Khokhar1,5 ✉
Alcohol use disorder commonly occurs in patients with schizophrenia and signiﬁcantly worsens the clinical course of the disorder.
The neurobiological underpinnings of alcohol drinking are not well understood. Magnetic resonance spectroscopy (MRS) has been
used to assess the neurochemical substrates that may be associated with alcohol drinking in patients; however, the causal impact of
these ﬁndings remains elusive, highlighting the need for studies in animal models. This study performed MRS in the neonatal
ventral hippocampal lesioned (NVHL) rat model, a model of co-occurring schizophrenia and substance use disorders. NVHL lesions
(or sham surgeries) were performed on post-natal day 7 and animals were given brief exposure to alcohol during adolescence (10%
v/v in a 2-bottle choice design). Animals were re-exposed to alcohol during adulthood (20% v/v) until a stable drinking baseline was
established, and then forced into abstinence to control for the effects of differential alcohol drinking. Animals were scanned for
MRS after one month of abstinence. NVHL rats consumed signiﬁcantly more alcohol than sham rats and in the cingulate cortex
showed signiﬁcantly higher levels of GABA and glutamine. Signiﬁcantly lower GABA levels were observed in the nucleus
accumbens. No differences between the NVHL and sham animals were observed in the hippocampus. Correlation analysis revealed
that GABA and glutamine concentrations in the cingulate cortex signiﬁcantly correlated with the rats’ alcohol drinking prior to
30 days of forced abstinence. These ﬁndings suggest that a potential dysfunction in the glutamate/GABA–glutamine cycle may
contribute to alcohol drinking in a rat model of schizophrenia, and this dysfunction could be targeted in future treatment-focused
studies.
Schizophrenia (2022)8:67 ; https://doi.org/10.1038/s41537-022-00272-6

INTRODUCTION
Alcohol use disorders (AUD) commonly occur in patients with
schizophrenia (43–65%)1; this use signiﬁcantly worsens the course
of the disorder contributing to poor treatment response,
treatment non-compliance2, relapse3,4, violence5,6, and suicide7,8.
Unfortunately, both the current understanding of, and treatment
options for, co-occurring alcohol use in patients with schizophrenia are limited. The most effective current treatment, the
atypical antipsychotic clozapine, is rarely used due to its sideeffect proﬁle9, underscoring the need to new treatment development and investigation of potential therapeutic targets.
While the self-medication hypothesis is often used to explain
alcohol and other substance use in patients with schizophrenia,
we, and others, have advanced an alternative unifying hypothesis
that suggests that co-occurring substance use may be related to
shared genetic susceptibility or brain reward circuit dysfunction,
that makes these patients especially vulnerable to the effects of
substances10–12. Altered glutamatergic neurotransmission in
particular has been heavily implicated in both schizophrenia and
alcohol use disorder and may provide a potential mechanistic link
to the neurobiological underpinnings of the increased predisposition to alcohol drinking13. Previous work has suggested that
alterations in glutamine-glutamate metabolism may in fact
predate alcohol abuse14, leading to the question of whether
schizophrenia-induced glutamatergic dysfunction may be a

contributor to AUD. However, glutamatergic neurotransmission
remains difﬁcult to measure in-vivo, thereby making it difﬁcult to
quantify dysfunction in the glutamate/GABA–glutamine cycle15.
Proton magnetic resonance spectroscopy (MRS) is a useful
methodology that is often used to study the neurochemical
correlates of psychiatric illness. Particularly relevant to this study,
MRS allows for the assessment of glutamatergic function and
dysfunction via the measurement of in-vivo concentrations of
amino acid-based neurotransmitters and their metabolites (i.e.,
GABA, glutamine, and glutamate) within speciﬁc regions of the
brain speciﬁed by three-dimensional spectroscopy voxels. Employing this technique in rodent models can allow for replication into
animal models of metabolite concentration changes reported in
MRS studies of human patients for further validation of the
models, to establish causality, to identify therapeutic targets, and
to use MRS measurements as outcome measures in treatment
development.
Compounding the difﬁculty of detecting subtle neurobiological
alterations, is the difﬁculty in developing accurate heuristic
models in animals that adequately capture the features of clinical
presentation in humans; this process becomes particularly difﬁcult
when modeling co-occurring disorders such as schizophrenia and
AUD16. To model “dual-diagnosis” in patients, we employed an
established animal model of schizophrenia and co-occurring
alcohol use disorder built upon the neonatal ventral hippocampal
lesioned (NVHL) rat17–19, which is one of the best-described animal
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models of SCZ20. This animal (experimentally created by producing an excitotoxic lesion in the ventral hippocampus in a 7-day
old rat) has strong construct, face, and predictive validity for
schizophrenia21, and displays behavioral and neurobiological
dysfunctions analogous to those seen in patients with schizophrenia. Moreover, like patients with schizophrenia1, NVHL rats
display enhanced sensitivity to, and increased use of, alcohol22,23,
cocaine24–26, nicotine27, ketamine28, and methamphetamine29 as
well as altered rewarding effects of cannabinoids30,31. It has been
shown that this model shows consistent circuit dysfunctions with
those observed in patients with schizophrenia, and that cannabis
vapor exposure can worsen these dysfunctions19,32. We have
recently shown that the NVHL rat model of schizophrenia and
alcohol use disorder, initially described by ref. 22, can be used to
understand the behavioral and neurobiological underpinnings of
this disorder, speciﬁcally showing that impairments in switching
behaviors (as measured by a latent inhibition of autoshaping task)
contribute to the risk for alcohol drinking in this model17.
In this study, we utilized MRS in the cingulate cortex, nucleus
accumbens, and hippocampus to assess the relationship between
glutamatergic dysfunction and alcohol drinking in a rat model of
co-occurring AUD and schizophrenia. Glutamine and glutamate
levels are known to normalize to baseline levels by 3-weeks after
last alcohol exposure33, therefore NVHL rats with established
alcohol drinking were forced into abstinence for a month. We
aimed to replicate and extend previous ﬁndings from abstinent
patients with a history of alcohol use disorder14 while ensuring
that the differential levels of drinking between the NVHL and
sham rats did not confound our ﬁndings. Further, based on these
previous ﬁndings14, we hypothesized that glutamatergic dysfunction would correlate with alcohol consumption prior to 30-day
abstinence, supporting a potential contributing effect of this
dysfunction to alcohol drinking in our model, and by extension to
AUD in patients with schizophrenia.
METHODS AND MATERIALS
Subjects
Timed pregnant Sprague-Dawley dams were ordered from Charles River
(Wilmington, MA) to arrive at gestational day 13 and were singly housed
with ad libitum access to food and water. Male rat pups used in the study
were individually housed in a colony room maintained on a 14:10 h lightdark cycle. Experimentation took place during the light period of the cycle.
Rats were monitored and cared for in compliance with the Association for
Assessment and Accreditation of Laboratory Care guidelines and the
IACUC of Dartmouth College.

NVHL preparation and surgery
Male Sprague-Dawley rat pups (n = 11) on post-natal day 7 (PND 7,
15–20 g) were anesthetized using hypothermia and placed on a Styrofoam
platform attached to a stereotactic apparatus (Kopf Instruments, Tujunga).
For the NVHL group, pups (n = 6) were bilaterally injected with excitotoxic
ibotenic acid (3.0 μg ibotenic acid [Tocris, Minneapolis] dissolved in 0.3 μl
of artiﬁcial cerebrospinal ﬂuid (aCSF; 150 μM Na, 3.0 μM K, 1.4 μM, Ca,
0.8 μM Mg, 1.0 μM P, and 155 μM Cl; pH 7.4)34 into their ventral hippocampi
(AP −3.0 mm, ML ± 3.5 mm, VD ± 5.0 mm relative to bregma). The
remaining pups (n = 5) were injected with aCSF at the same coordinates
(Sham, unlesioned). After the surgery, wounds were closed using tissue
glue, and rats were returned to their dams when activity level had returned
to normal. On PND21, rats were weaned and housed individually for the
duration of the study to allow for individual measurement of alcohol
drinking.

rats only had access to water until they reached adulthood. Water, alcohol,
and food intake as well as body weight were measured daily during PND
28–42 and then again in adulthood upon resumption of alcohol drinking.
Alcohol was then reintroduced to the rats in adulthood (PND 90) in a
continuous-access 2-bottle choice (water and 20% alcohol v/v) design. The
two bottles were rotated daily to prevent positional preference, consistent
with our previous investigations35. Animals were allowed to drink until
their drinking stabilized (4 days with less than 10% variance in drinking)
and were allowed to drink at these levels for 30 days, followed by forced
abstinence. Since glutamine and glutamate levels normalize to baseline
levels by 3-weeks after last alcohol exposure33, we chose to scan the
animals 30 days after the last alcohol drinking day.

MRI methods
All MRI scans were performed on an Agilent 9.4T animal scanner using
VnmrJ 4.0A software located at the Dartmouth-Hitchcock Medical Center,
with a RAPID 2 channel volume coil as a transmitter and a 4-channel
phase-array surface coil as receiver. Rats were anesthetized with an
isoﬂurane-oxygen mixture (5% for induction and 2.0–2.5% for maintenance) and the respiration rate was maintained between 40 and 60
respiration per minute. The rectal temperature was kept at 36.5 °C using a
blown hot air system. The sagittal/axial anatomic images were acquired
using a multiple spin-echo sequence (TR/TE = 2000/12 ms, echo number =
8, average = 4) with the anterior commissure used as a landmark for axial
image positioning. Imaging voxel size was 0.16 × 0.16 × 1 mm3.
MRS data were acquired from the cingulate cortex (1.8 × 1.6 × 3.6 mm3),
dorsal hippocampus (1.8 × 0.8 × 2.6 mm3) and nucleus accumbens
(1.6 × 1.8 × 2.4 mm3) using the spectroscopic voxels listed. For all acquisitions, an optimized short TE PRESS sequence (TE/TR = 14/2000 ms) was
used. The spectroscopic voxel sizes and precise locations of placement
were chosen according to ref. 36 and inclusion of CSF and white matter in
the voxels was minimized. 3D shimming was performed before each MRS
acquisition such that the linewidth of the water from each spectroscopic
voxel was <14 Hz. The number of averages used, and acquisition time were
768 (28 min), 1024 (38 min), and 1536 (56 min) for the cingulate cortex,
hippocampus, and nucleus accumbens, respectively. To minimize chemical
shift displacement error for neurotransmitters of interest (Glu, Gln, GABA),
the center frequencies of the localization radiofrequency pulses of the
PRESS sequence were set to 2.3 ppm. Water suppression was performed
using the variable pulse power and optimized relaxation delays water
suppression (VAPOR) scheme37 using Gaussian-shaped suppression pulses
with a bandwidth of 200 Hz, prior to acquisition of water-suppressed MRS
data. For each region, unsuppressed water signal was also acquired using
the same sequence, except with the RF pulses turned off during the VAPOR
scheme. For acquisition of the water signal, the RF pulses were centered on
the water signal at 4.7 ppm. Data were acquired in a metabolite-water
interleaved fashion, with 16 averages of unsuppressed water signal
acquired between 8-min blocks of water-suppressed acquisition (256
averages).
Preprocessing of the MRS data was performed in the console software
VnmrJ 4.0 with macros written in-house. Signals from different coil
channels were combined, and phase and frequency corrections of watersuppressed metabolite spectra were done. Since acquisition was done in
an interleaved fashion, metabolite spectra acquired during each 8-minute
block were phase and frequency corrected using the water spectrum
acquired afterward as a reference, for the slow drifts caused by the magnet
and potential animal movements during the long acquisition time.
Processing of acquired metabolite spectra, spectral ﬁtting, and metabolite
quantiﬁcation was performed with LCModel38 version 3.6-1H. A basis set
consisting of simulated metabolite spectra produced in VeSPA39 with the
same acquisition parameters and an experimentally acquired macromolecule spectrum were provided to LCModel for spectral ﬁtting. The
macromolecule spectrum was acquired from a whole brain spectroscopic
voxel and was included in the basis set to account for the macromolecule
baseline present in the spectra due to the short TE used. The unsuppressed
water signal was provided to LCModel for both the eddy current correction
as well as the reference signal for metabolite concentration calculation.

Alcohol drinking in adolescence and adulthood
To ensure that the NVHL rats would be susceptible to drinking alcohol
preferentially in adulthood, we followed the protocol of Jeanblanc et al.22,
in which the rats were given access to alcohol in a free-access 2-bottle
(water and 10% alcohol v/v in spill-proof bottles) design between PND 28
and 42. At the end of this period, the alcohol bottle was removed, and the
Schizophrenia (2022) 67

Lesion veriﬁcation and analysis
After euthanasia, the rat brains were removed and ﬂash frozen. Lesions
were veriﬁed via 40 mm sections of the dorsal and ventral hippocampus
using a freezing microtome, that were mounted on glass slides and thionin
stained. The hippocampus was examined for bilateral damage
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Fig. 1 Schematic and representative photomicrographs depicting lesion extent and location in NVHL rats. Arrows point to a lesion in a
representative NVHL rat’s ventral hippocampus photomicrographs (right) compared to a sham rat (left).
microscopically (typically includes cell loss, thinning, cellular disorganization, and ventricular enlargement).

Data analysis
An unpaired Student’s t-test was applied to compare alcohol consumption
between the Sham and NVHL groups and neurometabolite concentration
between the Sham and NVHL groups. When statistically signiﬁcant
differences were detected in neurometabolite concentrations a Pearson
correlation analysis was used to determine the correlation between alcohol
drinking and neurometabolite concentration. For all statistical analysis,
p < 0.05 was taken as statistically signiﬁcant. The data that supports the
ﬁndings of this study is available from OSF at https://osf.io/d8xrs/.

RESULTS
Histology
All NVHL rats displayed bilateral lesions of the hippocampus,
whereas no lesions were observed in the sham animals.
Representative photomicrographs depicting lesion location and
extent are presented in Fig. 1.
MRS
Figure 2 shows a representative LCModel ﬁtting of spectra in the
cingulate cortex, hippocampus, and nucleus accumbens of NVHL
and sham rats with the spectroscopic voxel marked on axial/
sagittal images. Quality control data including the linewidth, SNR,
and the Cramer-Rao lower bound are summarized in Table 1.
Alcohol consumption
Alcohol consumption was measured as an average of the last three
days before forced abstinence in both the sham and NVHL groups.
Consistent with our previous ﬁndings, results of the t-test revealed
NVHL rats drank signiﬁcantly more alcohol than the sham group
(NVHL = 4.65 ± 0.77 g/kg, Sham = 2.92 ± 0.78 g/kg, p < 0.001, Fig.
3). No differences in alcohol drinking were observed between
NVHL and sham rats during adolescence.

Neurometabolites
In the cingulate cortex of the NVHL group, a t-test revealed both
GABA and Gln concentrations were statistically signiﬁcantly higher
than the sham group (GABA: p = 0.0061, Cohen’s d: 5.0365; Gln:
p = 0.0412, Cohen’s d: 3.1967), while Glu showed no statistically
signiﬁcant difference. In the nucleus accumbens of the NVHL
group only GABA concentrations were statistically signiﬁcantly
lower than the sham group (p = 0.0367, Cohen’s d: 3.2347), while
Gln and Glu showed no statistically signiﬁcant difference. There
were no statistically signiﬁcant differences in concentrations of the
three metabolites in the hippocampus. Table 2 and Fig. 4 provide
the complement of results of metabolites in all three brain regions
in both groups.
Correlation analysis
Performing a Pearson correlation between alcohol drinking (taken
as the average of the last 3 days of alcohol drinking prior to
30 days of abstinence) and the neurometabolites as measured by
MRS, it was found that alcohol drinking showed a positive
correlation to both GABA and Gln in the cingulate cortex (GABA:
r(9) = 0.7662, p = 0.0060, Cohen’s d: 2.3847; Gln: r(9) = 0.7497,
p = 0.0079, Cohen’s d: 2.2657). No other statistically signiﬁcant
correlations were found. Refer to Table 3 and Fig. 5 for full results.
DISCUSSION
This study utilized MRS to assess the relationship between
glutamatergic dysfunction and alcohol drinking in a neurodevelopmental rat model of co-occurring AUD and schizophrenia.
Consistent with our previous ﬁndings, the NVHL rats showed
signiﬁcantly higher alcohol consumption (who then underwent
30 days of abstinence prior to being scanned for neurometabolite
levels). Proton MRS in the cingulate cortex revealed signiﬁcantly
higher levels of GABA and glutamine while signiﬁcantly lower
GABA levels were also observed in the nucleus accumbens. No
differences in neurometabolite levels in the hippocampus were
observed between the NVHL and sham animals. In the cingulate
cortex both GABA and glutamine showed a positive correlation
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Fig. 2 LCModel ﬁtting and voxel positions. LCModel ﬁttings (red
line) of the experimental spectra (black line) of the cingulate cortex
(top), hippocampus (middle), and nucleus accumbens (bottom) of
representative NVHL and sham rats, with inset showing the voxel
position.

with the amount of alcohol consumed prior to 30 days of forced
abstinence. No statistically signiﬁcant changes were observed in
the hippocampus, despite being the site of the lesions; it should
be noted though that MRS was collected in the dorsal
hippocampus. These ﬁndings provide support that glutamatergic
dysfunction may be related to alcohol drinking and may
Schizophrenia (2022) 67

contribute to co-occurring alcohol use disorder in patients with
schizophrenia.
While the neurometabolic correlates of dual-diagnosis schizophrenia and alcohol have not been studied explicitly, glutamatergic dysfunction is known to occur in both schizophrenia alone and
in AUD alone. The increased glutamine observed in the cingulate
cortex in our study is consistent with previous reports in
pharmacological animal models of schizophrenia40 and in patients
with schizophrenia41,42. Our ﬁndings of the elevated GABA in the
same region are in line with a recent report on chronic
schizophrenia43, while the reduced GABA levels in the nucleus
accumbens of decreased GABA are also consistent with postmortem ﬁndings from patients with schizophrenia44, consistent
with decreases in glutamic acid decarboxylase 67 (GAD67, the
enzyme that converts glutamate to GABA) mRNA in the nucleus
accumbens in patients with schizophrenia45. Further, the increase
in glutamine in the cingulate cortex has also been observed in
human subjects with current AUD and those in remission14.
Together, these ﬁndings indicate that the dysfunction of the
glutamate/GABA–glutamine cycle observed in the NVHL model
appears to be similar to the dysfunctions seen in patients with
schizophrenia and/or AUD alone. Interestingly, no differences in
neurometabolite levels in the dorsal hippocampus were observed.
These ﬁndings contrast previous studies which suggest lower
GAD67 expression in the dorsal hippocampus46; however, these
ﬁndings were speciﬁc to the CA1 region suggesting that the dorsal
hippocampus voxel may not have captured the sub-region-related
changes. Importantly, to our knowledge, none of the MRS studies
of patients with schizophrenia have focused on the posterior
hippocampus (dorsal hippocampus in primates)47. These ﬁndings
lend some support for the NVHL model as a potentially useful
heuristic studying schizophrenia and alcohol use disorder, which
we can now begin to manipulate pharmacologically toward
treatment development. However, it is possible that the neurometabolic correlates of the co-occurring disorder are distinct from
those of the two disorders alone, thereby supporting the need for
more studies in dual diagnosis patients to gain a better understanding of the mechanisms contributing to the development of
AUD in patients with schizophrenia.
Previous work has shown that glutamine and glutamate levels
normalize to baseline levels by 3-weeks after last alcohol exposure
in the rat brain33. In order to control for the potential effects of the
higher levels of alcohol drinking in the NVHL rats, rats in this study
were forced into abstinence for 30 days prior to MRS acquisition;
therefore, the higher glutamine levels are unlikely to be due to the
effects of higher alcohol consumption or withdrawal from alcohol
drinking. The presence of the higher glutamine levels even after
these 30 days, and the correlation between GABA and glutamine
levels and past drinking, also supports previous hypotheses from
studies in patients with AUD14 that glutamatergic dysfunction may
predate alcohol exposure and could contribute to the vulnerability
for AUD in patients (with or without schizophrenia). Another
recent study in patients with AUD undergoing monitored
abstinence found prospective associations between anterior
cingulate glutamine levels (but not GABA which was found to
be signiﬁcantly increased) and heavy drinking, craving and
withdrawal symptoms48. This is further supported by MRS studies
in substance-naïve adolescents with a family history of AUD,
where the glutamine to glutamate ratio correlated with impulsive
behaviors, suggesting a role for glutamatergic dysfunction in the
vulnerability toward alcohol use49. Moreover, craving during
detoxiﬁcation in alcohol-dependent individuals is also related to
combined glutamine-glutamate levels in the cingulate cortex50.
However, it is still possible that the higher levels of alcohol
drinking and withdrawal in the NVHL rats contributed to increases
in the packing density of glutamine synthetase expressing
astrocytes51, which might have contributed to the greater
conversion of glutamate to glutamine. Alternatively, since
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Table 1. Cramer-Rao lower bound (CRLB), Linewidth (Hz), and Signal to Noise Ratio (SNR) of the cingulate cortex, hippocampus, and nucleus
accumbens of all spectra.
CRLB

Linewidth (Hz)

SNR

GABA

Glu

Gln

Cingulate Cortex
Hippocampus

23 ± 7%
28 ± 8%

4.0 ± 0.3%
7 ± 2%

15 ± 5%
24 ± 9%

9±2
8±2

18 ± 4
14 ± 2

Nucleus Accumbens

26 ± 6%

7 ± 1%

18 ± 8%

10 ± 2

9±4

Table 2. Average concentrations (mM ± Standard Deviation) of GABA,
glutamine (Gln), and glutamate (Glu) in the cingulate cortex,
hippocampus, and nucleus accumbens of NVHL and sham rats.
Averaged Concentrations (mM ± Standard Deviation) for Neurometabolites
GABA
Cingulate Cortex
Sham
2.7262 ±
NVHL
3.7113 ±
p value
0.0061*
Nucleus Accumbens
Sham
2.9850 ±
NVHL
1.9210 ±
p value
0.0367*
Hippocampus
Sham
3.6268 ±
NVHL
3.4128 ±
p value
0.6385

Fig. 3 Higher levels of alcohol drinking in NVHL rats compared to
sham rats. NVHL rats drank signiﬁcantly more alcohol than the
sham group measured as an average of the last 3 days before
withdrawal (sham = 2.92 ± 0.78 g/kg, NVHL = 4.65 ± 0.77 g/kg).
Statistically signiﬁcant differences are denoted by * (p < 0.001;
n = 6 NVHL, 5 sham). Data are shown as mean ± SD. Individual data
points are denoted with a (+) Sham or (x) NVHL.

Glutamine

Glutamate

0.2033
0.1875

3.6062 ± 0.4337
4.7500 ± 0.2520
0.0412*

14.3130 ± 0.7289
15.4058 ± 0.4597
0.2212

0.4319
0.1728

5.5076 ± 0.8892
5.0982 ± 0.5079
0.6858

11.7468 ± 0.8883
12.7987 ± 0.4506
0.2940

1.1933
0.4944

4.7470 ± 0.6458
4.4908 ± 1.7322
0.2722

13.0428 ± 1.3991
13.5497 ± 1.3989
0.1184

Values showing statistically signiﬁcant differences (p < 0.05) between
groups are bolded and represented with *. Data are shown as mean ± SD.

Fig. 4 Higher cingulate glutamine and GABA, but lower nucleus accumbens GABA, levels in NVHL rats. In the cingulate cortex (A), GABA
and glutamine concentrations were signiﬁcantly higher in the NVHL rat compared to the sham rats. In the nucleus accumbens (B) of the NVHL
group, GABA concentrations were signiﬁcantly lower than the sham group. No differences between groups were observed in the dorsal
hippocampus (C). Statistically signiﬁcant differences between groups are represented with * (p < 0.05; n = 6 NVHL, 5 sham). Data are shown as
mean ± SD. Individual data points are denoted with a (+) Sham or (x) NVHL.

astrocytic genes are often upregulated in brains from patients
with schizophrenia52, it is possible that the higher levels of
glutamine are related to such upregulation in the NVHL rat, and
not due to alcohol drinking. Future studies will assess neurometabolite levels prior to initiation of alcohol drinking to assess the
potential predictive potential of cingulate cortex glutamine levels
on alcohol drinking, while also uncovering what roles alcohol

drinking and astrocyte expression might contribute to the
glutamatergic dysfunction observed here.
The current study does have some limitations, the most
important of which is the lack of sham and NVHL groups with
no alcohol exposure during adolescence. This limits our ability to
assess the differential effect of adolescent alcohol exposure as it
relates to the NVHL model (aside from its known impact on
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Fig. 5 Glutamine and GABA levels in the cingulate cortex correlate with alcohol drinking prior to abstinence. Pearson correlation between
(left) alcohol consumption (g/kg) and GABA (mM), and (right) alcohol consumption (g/kg) and glutamine concentration (mM) in the cingulate
cortex. Alcohol drinking showed a positive correlation between both GABA (r(9) = 0.7662, p = 0.0060) and glutamine concentration
(r(9) = 0.7497, p = 0.0079) as measured by magnetic resonance spectroscopy (MRS) (n = 6 NVHL, 5 sham). Individual data points are denoted
with a (+) Sham or (x) NVHL.

other psychiatric disorders such as bipolar disorder and major
depressive disorder, making it a potentially valuable transdiagnostic target for treatment development15. With growing
evidence of glutamat-/GABA-ergic dysfunction predating AUD in
patients (with or without schizophrenia), more targeted treatment
options tackling this dysfunction may be explored to limit the
detrimental effect alcohol consumption may have on these
patients.

Table 3.

Pearson Correlation analysis of alcohol consumption (g/kg)
and neurometabolites (mM).
Alcohol
and GABA

Alcohol and
Glutamine

Alcohol and
Glutamate

Cingulate Cortex
Pearson r

0.7662

0.7497

0.3919

t

3.5769

3.3987

1.2779

p value

0.0060*

0.0079*

0.2332

Nucleus Accumbens
Pearson r −0.3599

−0.2121

t

1.1576

0.6510

1.015

p value

0.2768

0.5313

0.3364

CONCLUSION
Consistent with previous studies in patients with schizophrenia,
glutamatergic dysfunction was observed in the cingulate cortex
of NVHL rats. NVHL rats consumed signiﬁcantly more alcohol
than sham rats and had signiﬁcantly higher levels of GABA and
glutamine in the cingulate cortex as well as signiﬁcantly lower
levels of GABA in the nucleus accumbens. GABA and glutamine
showed a positive correlation with alcohol consumption across
all animals (measured as the last 3 days of alcohol drinking prior
to 30 days abstinence). These ﬁndings provide additional
support for the hypothesis that glutamat-/GABA-ergic dysfunctions may contribute to the vulnerability for alcohol drinking,
while providing a potential avenue where schizophreniainduced neurometabolic dysfunctions may give rise to a shared
susceptibility for both schizophrenia and the development
of AUD.

0.3206

Hippocampus
Pearson r −0.0495

−0.0956

−0.2204

t

0.1486

0.2881

0.6780

p value

0.8852

0.7798

0.5148

Alcohol drinking showed a positive correlation to both GABA
(r(9) = 0.7662, p = 0.0060) and Glutamine concentration (r(9) = 0.7497,
p = 0.0079) as measured by Magnetic Resonance Spectroscopy (MRS)
(n = 6 NVHL, 5 sham).
Values showing statistically signiﬁcant differences (p < 0.05) between
groups are bolded and represented with *.

inducing alcohol drinking in adulthood). It could be the NVHL
surgery, the alcohol drinking during adolescence, or the interaction
between these factors, has led to the glutamatergic dysfunction
observed in the current study. Furthermore, the limited sample
sizes do not permit robust correlations using only the NVHL rats,
which might have been useful in understanding whether the
differences in neurometabolite levels relate just to the differences
in alcohol drinking between NVHL or sham animals (both of which
drink different amounts of alcohol) or are related to other factors
that may contribute to this dysfunction (e.g., NVHL lesion).
Therefore, these results must be interpreted with caution. Follow
up studies will attempt to determine the nature of impact of
adolescent alcohol drinking on the neurometabolic dysfunctions in
NVHL rats utilizing a group without adolescent alcohol exposure.
Abnormal glutamatergic neurotransmission or metabolism has
been previously linked to both schizophrenia and AUD, but also to
Schizophrenia (2022) 67
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